Implications of edge cases for antimicrobial susceptibility predictions for rifampin, delamanid, and pretomanid with the WHO Mycobacterium tuberculosis mutation catalog
Microbiology Spectrum · 2026
DOI: 10.1128/spectrum.01821-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Noud Hermans und 24 weiteren Autor:innen. Beteiligte Einrichtung: Diagnostics Team, Division of Tuberculosis Elimination & Health Systems Innovations, KNCV Tuberculosis Foundation, The Hague, The Netherlands. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Rifampin, Nitroimidazoles, Antitubercular Agents. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, MRC Centre for Global Infectious Disease Analysis, EPSRC.
Abstract (Originalsprache)
The WHO mutation catalog is the reference for genotypic antimicrobial susceptibility predictions (ASPs) for Mycobacterium tuberculosis . To increase sensitivity, WHO endorsed additional grading rules to classify mutations with insufficient experimental evidence. For rifampin, this includes any non-silent rpoB mutation in the rifampin resistance-determining region (RRDR). For delamanid and pretomanid, the rules include loss-of-function (LoF) variants in six resistance genes, including fbiC . Here, we describe three edge cases in which these additional grading rules overcalled resistance. The first case was a low-frequency rpoB variant in RRDR caused by a sequencing artifact. The second case involved a tandem repeat region starting at the end of fbiC . Because the H37Rv reference genome carries 2.7 repeats, deletion of one or two full repeats caused mapping errors, making these deletions appear as minority variants that trigger the fbiC LoF rule. However, assembly showed that these deletions did not affect the fbiC coding region because the remaining repeat substituted for the deleted repeats. The third case was a fbiC frameshift in lineage 4.6.1 Uganda genotype strains, caused by a 19 bp duplication upstream of the same tandem repeat region. Although this frameshift affects the fbiC coding region and meets the fbiC LoF rule, sequence assembly revealed only a modest impact on the end of fbiC . Although catalog performance remains high, WHO and others have acknowledged that, in specific situations, exceptions to its additional grading rules may result in unintended overcalling of resistance. Thus, systematic external quality control and communication of edge cases are essential. IMPORTANCE Antimicrobial susceptibility predictions (ASPs) for Mycobacterium tuberculosis using next-generation sequencing and the WHO mutation catalog are increasingly used for clinical decision-making. This avoids systematic false-resistant results of real-time PCR- or hybridization-based ASP assays caused by mutations that do not confer resistance (e.g., synonymous rifampin resistance-determining region [RRDR] mutations) and, potentially, subsequent inappropriate treatment adjustments. However, we demonstrate that false-resistant results occur even using the WHO mutation catalog for rifampin, delamanid, and pretomanid. Similar exceptions linked to the additional grading rules of the catalog are possible for other drugs, underlining the importance of monitoring the performance of the catalog continuously.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diagnostics Team, Division of Tuberculosis Elimination & Health Systems Innovations, KNCV Tuberculosis Foundation, The Hague, The Netherlands.
- Department Bacterial Surveillance and Response, Center for Infectious Disease Control, Diagnostics and Laboratory Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
- Department of Infection Biology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
- Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- National and WHO-Supranational Reference Laboratory for Mycobacteria, Leibniz Lung Center, Borstel, Germany.
- Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection & Immunity, Melbourne, Victoria, Australia.
ORCID-Profile: Noud Hermans, Jody Phelan, Rita Sorrentino, Fenja Boysen, Norelle L Sherry, Paolo Miotto, Daniela Maria Cirillo, Leonid Chindelevitch, Timothy C Rodwell, Ivan Barilar, Stefan Niemann, Sönke Andres, Alexander Mischnik, Kristy Horan, Katherine Bond, Maria Globan, Mor Rubinstein, Yelena Losev, Taane G Clark, Satoshi Mitarai, Altyn Iskakova, Andrii Slyzkyi, Claudio U Köser, Kristin Kremer, Richard Anthony
Förderung
- NIAID NIH HHS
- MRC Centre for Global Infectious Disease Analysis
- EPSRC
- UKRI MRC
- National Health Research Council Australia
- StopTB Partnership
- NIH NIAID
- Dutch Postcode Lottery, and the Dutch Ministry of Health, Welfare and Sports
Zitieren
APA
Hermans, N., Phelan, J., Sorrentino, R., Boysen, F., Sherry, N. L., Miotto, P., Cirillo, D. M., Chindelevitch, L., Rodwell, T. C., Barilar, I., Niemann, S., Andres, S., Mischnik, A., Horan, K., Bond, K., Globan, M., Rubinstein, M., Losev, Y., Clark, T. G., …, & Anthony, R. (2026). Implications of edge cases for antimicrobial susceptibility predictions for rifampin, delamanid, and pretomanid with the WHO Mycobacterium tuberculosis mutation catalog. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01821-26
Vancouver
Hermans N, Phelan J, Sorrentino R, Boysen F, Sherry NL, Miotto P, et al. Implications of edge cases for antimicrobial susceptibility predictions for rifampin, delamanid, and pretomanid with the WHO Mycobacterium tuberculosis mutation catalog. Microbiology Spectrum. 2026. doi:10.1128/spectrum.01821-26
BibTeX
@article{Hermans2026,
author = {Hermans, Noud and Phelan, Jody and Sorrentino, Rita and Boysen, Fenja and Sherry, Norelle L and Miotto, Paolo and Cirillo, Daniela Maria and Chindelevitch, Leonid and Rodwell, Timothy C and Barilar, Ivan and Niemann, Stefan and Andres, Sönke and Mischnik, Alexander and Horan, Kristy and Bond, Katherine and Globan, Maria and Rubinstein, Mor and Losev, Yelena and Clark, Taane G and Mitarai, Satoshi and Iskakova, Altyn and Slyzkyi, Andrii and Köser, Claudio U and Kremer, Kristin and Anthony, Richard},
title = {Implications of edge cases for antimicrobial susceptibility predictions for rifampin, delamanid, and pretomanid with the WHO Mycobacterium tuberculosis mutation catalog},
journal = {Microbiology Spectrum},
year = {2026},
doi = {10.1128/spectrum.01821-26}
}
EUVIMED